Johnson & Johnson to Acquire Yellow Jersey Therapeutics for $1.25 Billion, Bolstering Atopic Dermatitis Pipeline
核心洞察
Johnson & Johnson will acquire Yellow Jersey Therapeutics (搜索) for $1.25 billion, gaining rights to NM26, a Phase 2-ready bispecific antibody for atopic dermatitis (搜索).
NM26 targets both IL-4Rα (搜索) and IL-31 (搜索), addressing inflammation and itch, potentially offering advantages over existing treatments like Dupixent.
The acquisition aligns with J&J's strategy to expand its immunology portfolio with differentiated bispecifics, following recent deals in oncology and immunology.
Johnson & Johnson (J&J) is set to acquire Yellow Jersey Therapeutics (搜索), a subsidiary of Numab Therapeutics (搜索), for $1.25 billion, securing rights to NM26, a bispecific antibody poised for Phase 2 clinical trials in atopic dermatitis (搜索). This move strengthens J&J's immunology pipeline and reflects its strategic focus on bispecific antibodies.
NM26: A Dual-Targeting Approach to Atopic Dermatitis
NM26 is a bispecific antibody that simultaneously targets IL-4Rα (搜索) (type I and type II receptors) and IL-31 (搜索), two key proteins implicated in the pathophysiology of atopic dermatitis (搜索). IL-4Rα is crucial in signaling pathways that drive inflammation, while IL-31 is associated with pruritus (itching), a hallmark symptom of the disease. By targeting both pathways, NM26 aims to provide more comprehensive relief compared to existing therapies.
"Our investment in differentiated bispecifics is the next chapter in our impactful immunology legacy," said Candice Long, J&J’s global vice president of immunology.
Strategic Fit for Johnson & Johnson
The acquisition aligns with J&J's broader strategy to develop 20 new medicines by the end of the decade, with a strong emphasis on oncology and immunology. The company has been actively pursuing bispecific antibodies, as evidenced by its existing multiple myeloma drugs, Talvey and Tecvayli. J&J aims to build a portfolio of "differentiated and complementary bispecifics" across various disease areas.
Potential Advantages over Existing Therapies
NM26 may offer distinctive benefits compared to existing treatments like Sanofi and Regeneron's Dupixent (dupilumab) and AbbVie's Rinvoq (upadacitinib). While Dupixent targets pathways involved in skin inflammation, NM26 also addresses the itching component, potentially leading to improved patient outcomes. Numab has suggested that NM26 could be more potent and faster-acting than currently available options.
Numab's MATCH™ Technology
NM26 was discovered and engineered using Numab's proprietary MATCH™ technology platform, which facilitates the creation of multi-specific antibody drug candidates. This transaction validates the power of Numab's platform and its potential to generate novel therapeutics for underserved patient populations.
Deal Details and Future Plans
Under the agreement, J&J will gain full rights to develop, manufacture, and commercialize NM26 globally for atopic dermatitis (搜索) and potential follow-on indications. The closing of the transaction is expected in the second half of 2024, pending regulatory approvals. The $1.25 billion acquisition underscores the growing interest in bispecific antibodies as a promising therapeutic modality.